Payment overview · 2025
General Payments
$820.68
50 reported records · 13 companies
Healthcare provider profile · identity verified
Roberto Saez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BENTONVILLE, AR · NPI 1811925910
Verified facts
What the public records show
CMS Open Payments records show Roberto Saez, MD received $820.68 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 59.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $484.52 | 59.0% | 30 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.35 | 9.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.59 | 6.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.86 | 4.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.14 | 3.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.86 | 2.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.40 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.58 | 2.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.20 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.75 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.64 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.56 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.23 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $820.68 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $398.74 | 25 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $328.37 | 22 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.35 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $81.35 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.59 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 813 | 223 |
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 506 | 135 |
| Losartan Potassium | Losartan Potassium | 374 | 100 |
| Gabapentin | Gabapentin | 261 | 70 |
| Metformin Hcl Er | Metformin Hcl | 260 | 93 |
| Metformin Hcl | Metformin Hcl | 236 | 62 |
| Lisinopril | Lisinopril | 229 | 58 |
| Simvastatin | Simvastatin | 228 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 55 |
| Omeprazole | Omeprazole | 171 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 164 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 49 |
| Tramadol Hcl | Tramadol Hcl | 155 | 32 |
| Potassium Chloride | Potassium Chloride | 140 | 37 |
| Ozempic | Semaglutide | 123 | 31 |
| Ezetimibe | Ezetimibe | 121 | 35 |
| Alendronate Sodium | Alendronate Sodium | 118 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 48 |
| Furosemide | Furosemide | 111 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 27 |
| Bupropion Xl | Bupropion Hcl | 99 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 26 |
| Glimepiride | Glimepiride | 94 | 25 |
| Sertraline Hcl | Sertraline Hcl | 94 | 28 |
| Farxiga | Dapagliflozin Propanediol | 93 | 26 |
| Eliquis | Apixaban | 91 | 19 |
| Carvedilol | Carvedilol | 90 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 24 |
| Allopurinol | Allopurinol | 80 | 23 |
| Montelukast Sodium | Montelukast Sodium | 73 | 20 |
| Fenofibrate | Fenofibrate | 71 | 21 |
| Memantine Hcl | Memantine Hcl | 69 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 18 |
| Donepezil Hcl | Donepezil Hcl | 65 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Clonazepam | Clonazepam | 64 | 13 |
| Buspirone Hcl | Buspirone Hcl | 63 | 16 |
| Trazodone Hcl | Trazodone Hcl | 63 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 62 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Temazepam | Temazepam | 60 | suppressed |
| Finasteride | Finasteride | 58 | 21 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Meloxicam | Meloxicam | 57 | 22 |
| Irbesartan | Irbesartan | 56 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 17 |
| Spironolactone | Spironolactone | 51 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 15 |
| Jardiance | Empagliflozin | 45 | 15 |
| Estradiol | Estradiol | 44 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 12 |
| Atenolol | Atenolol | 40 | 11 |
| Prednisone | Prednisone | 39 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Digoxin | Digoxin | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Azithromycin | Azithromycin | 20 | 20 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Cefadroxil | Cefadroxil | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Alprazolam Odt | Alprazolam | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $820.68 · 50 records | ABBVIE INC. | AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, SYNTHROID, TZIELD, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error